DRIO vs. XAIR, PDEX, LYRA, PAVM, RCEL, TLSI, OBIO, PROF, DRTS, and CLPT
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include Beyond Air (XAIR), Pro-Dex (PDEX), Lyra Therapeutics (LYRA), PAVmed (PAVM), AVITA Medical (RCEL), TriSalus Life Sciences (TLSI), Orchestra BioMed (OBIO), Profound Medical (PROF), Alpha Tau Medical (DRTS), and ClearPoint Neuro (CLPT). These companies are all part of the "surgical & medical instruments" industry.
DarioHealth (NASDAQ:DRIO) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
DarioHealth received 194 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.75% of users gave Beyond Air an outperform vote while only 67.04% of users gave DarioHealth an outperform vote.
Beyond Air has a net margin of 0.00% compared to DarioHealth's net margin of -282.38%. DarioHealth's return on equity of -76.11% beat Beyond Air's return on equity.
33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 15.7% of DarioHealth shares are owned by company insiders. Comparatively, 19.0% of Beyond Air shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, DarioHealth had 2 more articles in the media than Beyond Air. MarketBeat recorded 3 mentions for DarioHealth and 1 mentions for Beyond Air. Beyond Air's average media sentiment score of 0.75 beat DarioHealth's score of 0.68 indicating that Beyond Air is being referred to more favorably in the news media.
DarioHealth has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.
Beyond Air has lower revenue, but higher earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
DarioHealth currently has a consensus target price of $4.05, suggesting a potential upside of 183.22%. Beyond Air has a consensus target price of $10.75, suggesting a potential upside of 739.84%. Given Beyond Air's higher probable upside, analysts plainly believe Beyond Air is more favorable than DarioHealth.
Summary
DarioHealth and Beyond Air tied by winning 8 of the 16 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
